Blog

  • Luciana Berger – 2016 Parliamentary Question to the Department of Health

    Luciana Berger – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Luciana Berger on 2016-01-13.

    To ask the Secretary of State for Health, with reference to paragraph 1.86 of the Autumn Statement 2014, how much of the planned annual £30 million additional budget for services for young people with eating disorders has been spent; and for what purposes that budget has been spent.

    Alistair Burt

    The whole £30 million for 2015/16 has been allocated directly to clinical commissioning groups. It is being spent on setting up new specialist community-based eating disorder teams. NHS England, in partnership with the National Collaborating Centre for Mental Health Services, developed the Children and Young People’s Eating Disorder Access and Waits Commissioning Guide, which was issued in August 2015 alongside the first tranche of money. The commissioning guide included detailed specifications on how to set up, train and support the teams.

    The aims of these new services are to support quicker access to evidence based treatment in the community and a reduction in the rate of relapse. In time, this should decrease the need for hospital stays and reduce the need for transition to adult services, although where there is still a need, the transitioning arrangements should be improved.

    This service will enable the introduction of an eating disorder standard for children and young people who are aged 18 and under, for treatment to be received within four weeks, from first contact with a designated health professional for routine cases and within one week for urgent cases.

  • Mark Prisk – 2016 Parliamentary Question to the Department of Health

    Mark Prisk – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Mark Prisk on 2016-01-13.

    To ask the Secretary of State for Health, if he will assess the effect of individual funding requests for palivizumab on premature babies at risk of severe complications from respiratory syncytial virus.

    George Freeman

    NHS England has advised that it is monitoring the level of individual funding requests for patients who do not meet the criteria for palivizumab. NHS England aims to finalise an analysis of this data in April 2016 and will report its findings to the neonatal care clinical reference group.

  • Stephen Kinnock – 2016 Parliamentary Question to the Department of Health

    Stephen Kinnock – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Stephen Kinnock on 2016-01-13.

    To ask the Secretary of State for Health, pursuant to the Answer of 17 December 2015 to Question 19788, in how many cases liability has been established for people infected by contaminated blood.

    Jane Ellison

    In 2001 the National Blood Authority was liable for the infection of 117 patients with hepatitis C between March 1988 and September 1991 by whole blood transfusion. The litigation was brought under the provisions of the Consumer Protection Act 1987. The litigants were awarded quantum based damages.

  • David Mackintosh – 2016 Parliamentary Question to the Department of Health

    David Mackintosh – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by David Mackintosh on 2016-01-13.

    To ask the Secretary of State for Health, if he will add pulmonary arterial hypertension to the conditions which are exempt from prescription charges.

    Alistair Burt

    There are no plans to change the list of medical conditions which provide exemption from prescription charges.

    Other extensive exemption arrangements are in place, in England, including those based on low income, which support those who cannot afford to pay for their prescriptions. For those who need multiple prescriptions and do not qualify for exemption, Prescription Prepayment Certificates (PPC) can be purchased, which allow someone to claim as many prescriptions as needed. A 12 month PPC costs £104 and benefits anyone who needs 13 or more prescriptions a year.

  • Jim Cunningham – 2016 Parliamentary Question to the Department of Health

    Jim Cunningham – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Jim Cunningham on 2016-01-13.

    To ask the Secretary of State for Health, what estimate his Department has made of the amount it will spend on (a) television, (b) print, (c) online and (d) billing advertising in the next 12 months.

    Jane Ellison

    The Department does not hold an advertising budget.

    As such there is no expected spend on advertising over the next 12 months other than that for the advertisement of public appointments.

  • Mark Durkan – 2016 Parliamentary Question to the Department of Health

    Mark Durkan – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Mark Durkan on 2016-01-13.

    To ask the Secretary of State for Health, what discussions the his Department, NHS England and NICE have had on the effect of proposed Cancer Drugs Fund (CDF) changes on patients prescribed current CDF treatments who will not receive interim funding under that proposed new scheme.

    George Freeman

    NHS England and the National Institute for Health and Care Excellence are currently consulting jointly on draft proposals on the future direction of the Cancer Drugs Fund (CDF). The consultation document states that all patients receiving treatment funded through the CDF on 31 March 2016 will continue to receive treatment until the point that they and their consultant agree that it is appropriate to stop.

    NHS England has advised that the aim of the future CDF is to help patients receive new treatments with genuine promise, while real world evidence is collected for up to two years on how well they work in practice. This will then help determine whether the treatment should be accepted for routine use in the National Health Service in the future. It is not possible to make comparisons between the current and future CDF until such time as the consultation has concluded and the responses reviewed.

    The consultation was published on 19 November 2015 and is open until 11 February 2016. Further information is available at:

    www.engage.england.nhs.uk/consultation/cdf-consultation

  • Flick Drummond – 2016 Parliamentary Question to the Department of Health

    Flick Drummond – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Flick Drummond on 2016-01-13.

    To ask the Secretary of State for Health, pursuant to the Answer of 12 October 2015 to Question 10658, if he will ensure that the national improvement framework for hepatitis C services contain guidance on the alignment of screening programmes for hepatitis C, HIV, tuberculosis and other blood-borne viruses or associated conditions.

    Jane Ellison

    Recommendations on testing for hepatitis C are evidence-based, including whether it is appropriate to align with guidance on testing for other conditions. It should be noted that the National Institute for Health and Care Excellence has already published guidance on testing for hepatitis B and C. Screening programmes are considered and recommended by the United Kingdom National Screening Committee.

  • Luciana Berger – 2016 Parliamentary Question to the Department of Health

    Luciana Berger – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Luciana Berger on 2016-01-13.

    To ask the Secretary of State for Health, how many and which health (a) trusts and (b) services (i) Jane Cummings, (ii) Dame Barbara Hakin, (iii) Paul Baumann, (iv) Karen Wheeler and (v) Ian Dodge have visited in each year since their appointments to the board of NHS England; and on what dates each such visit was held.

    George Freeman

    This information is not held by the Department. NHS England has advised that this information is not routinely collected and it could only be collated and provided at disproportionate cost.

  • Mark Durkan – 2016 Parliamentary Question to the Department of Health

    Mark Durkan – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Mark Durkan on 2016-01-13.

    To ask the Secretary of State for Health, if he will ask NHS England to publish a case study of the revised Cancer Drugs Fund (CDF) patient journey and give examples for how people are initiated onto CDF-approved treatments now and how people will be treated under the proposed new CDF scheme.

    George Freeman

    NHS England and the National Institute for Health and Care Excellence are currently consulting jointly on draft proposals on the future direction of the Cancer Drugs Fund (CDF). The consultation document states that all patients receiving treatment funded through the CDF on 31 March 2016 will continue to receive treatment until the point that they and their consultant agree that it is appropriate to stop.

    NHS England has advised that the aim of the future CDF is to help patients receive new treatments with genuine promise, while real world evidence is collected for up to two years on how well they work in practice. This will then help determine whether the treatment should be accepted for routine use in the National Health Service in the future. It is not possible to make comparisons between the current and future CDF until such time as the consultation has concluded and the responses reviewed.

    The consultation was published on 19 November 2015 and is open until 11 February 2016. Further information is available at:

    www.engage.england.nhs.uk/consultation/cdf-consultation

  • Kevin Barron – 2016 Parliamentary Question to the Department of Health

    Kevin Barron – 2016 Parliamentary Question to the Department of Health

    The below Parliamentary question was asked by Kevin Barron on 2016-01-13.

    To ask the Secretary of State for Health, what estimate he has made of the cost to the NHS of removing generic medicines required to have a brand name by the MHRA from the Statutory Scheme of Control the Prices of Branded Health Service Medicines.

    George Freeman

    The Department consulted on options to amend the Statutory Scheme regulations which control the prices of branded health service medicines. Both the voluntary Pharmaceutical Price Regulation Scheme and the statutory scheme include all health service medicines with a brand name, including those required by the Medicines and Healthcare products Regulatory Agency to have a brand name. The Department did not propose any changes to the scope of the statutory scheme in this respect and has not made an estimate of the cost of removing those branded medicines from the statutory scheme.

    The Department received responses from a range of organisations including National Health Service, independent bodies and pharmaceutical industry. The Department is currently analysing the responses from a range of organisations including NHS, independent bodies and pharmaceutical industry.

    The consultation and impact assessment can be accessed using the following link.

    https://www.gov.uk/government/consultations/pricing-of-branded-health-service-medicines